The Role of microRNAs in Gliomas and Their Potential Applications for Diagnosis and Treatment by Iris Lavon
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
The Role of microRNAs in Gliomas 
and Their Potential Applications 
for Diagnosis and Treatment  
Iris Lavon 
Leslie and Michael Gaffin Center for Neuro-Oncology and Department of Neurology, 
The Agnes Ginges Center for Human Neurogenetics,  
Hadassah Hebrew University Medical Center, Jerusalem, 
Israel 
1. Introduction 
MicroRNAs (miRNAs) are a class of single-stranded non-coding RNAs that average 22 
nucleotides in length. They regulate gene expression by binding to imperfectly matched 
sequences in the 3'-untranslated region (3'UTR) of target mRNAs, resulting in either 
translational repression or destabilization/degradation of their target mRNAs1-7. miRNAs 
play an important role in nearly all cancer types, where they modulate key tumorigenesis 
processes, such as metastasis, apoptosis, proliferation, and angiogenesis. Each miRNA can 
affect several different mRNAs and, depending on the target, has the potential to function as 
an oncogene and/or tumor suppressor. 
It has recently been shown that miRNAs play important roles in gliomas 8-19. A number of 
miRNAs, such as miR-21, miR-221, miR-222, miR-10b, and the miR-26a cluster 15,19, together 
with the genes cyclin-dependent kinase 4 (CDK4) and CENTG1, are upregulated in gliomas 
and appear to act in an oncogenic fashion. Other miRNAs, such as miR-1248, miR-1378, miR-
34a12,13, miR-12816, miR-32617 and members of the let-718 family, are downregulated 
indicating a tumor suppressive nature.  
Several important target mRNAs and pathways have been identified for these onco-
miRNAs and tumor suppressor miRNAs. For example, miR-34a is downregulated in 
glioblastomas as a result of p53 dysfunction, while restoring the expression of miR-34a12 or 
miR-718 in glioma cells can strongly inhibit oncogenic pathways, such as Ras and Akt.  
In addition to the singly transcribed miRNAs, our studies demonstrated that several miRNA 
clusters were shown to be deregulated in gliomas and might have an important role in the 
disease process. These clusters comprise the miR17 family, miR183-182, and the SC-specific 
clusters (miR367-302 and miR371-373), which are upregulated in gliomas. Because the 
massive cluster of 53 miRNAs on chromosome 14q32.31 is downregulated, it may represent 
the largest tumor suppressive miRNA cluster20. Some of these clusters, such as miR17-92, 
which is one of the three miRNA clusters related to the miR-17 family, reportedly have a 
pro-oncogenic roles in other type of cancers21. 
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We have recently shown that gliomas share miRNA expression profiles that are similar to 
neural precursor cells20. This result is in agreement with the finding that gliomas contain 
heterogeneous neoplastic cell populations that phenotypically resemble undifferentiated or 
immature glial cells.  
The study of miRNAs is rapidly developing and could considerably change the current 
conception of glioma biology. Detecting and quantifying microRNAs in tissue and serum 
will soon be routinely used for tumor classification and grading as well as diagnostic and 
prognostic testing for gliomas. For example, high levels of miR-21, miR-182 and miR-196 as 
well as low expression of miR-181b and miR-106a are associated with poor overall survival 
in patients with malignant gliomas22-24, and these miRNAs might function as biomarkers of 
glioma progression. Furthermore, miR-195, miR-455-3p, miR-10a25 and the miR-181 family26 
have been linked to treatment resistance, and assessing the relative expression levels of 
these miRNAs may assist with the design of personalized treatments. 
New knowledge regarding the involvement of miRNAs in glioma biology has provided 
opportunities for the use of miRNAs or their inhibitors as potential candidates for the brain 
tumor treatments. However, such a therapeutic approach may be considerably challenging 
in light of several barriers in vivo, such as the blood–brain barrier27, which can prevent 
miRNAs or their antagonists from entering the brain.  
2. MicroRNA regulation of gene expression 
miRNAs regulate gene expression inhibition through several proposed mechanisms. One 
model suggests that there is competition between RISC and eIF4E for mRNA binding, which 
represses initiation. A second model has proposed that Ago recruits eIF6 and, thus, prevents 
the association of the 60S ribosomal subunit with the 40S preinitiation complex28,29. The third 
model suggests that miRNAs destabilize target mRNAs by de-adenylation and subsequent 
decapping30-34. It was recently observed that AGO-2, mature miRNAs and translationally 
repressed mRNAs can accumulate in cytoplasmic processing bodies (P-bodies)35. These 
bodies are enriched with proteins involved in translational repression and in mRNA de-
adenylation, decapping and degradation. Thus, they might function not only in storage but 
also in the decay of repressed mRNAs. However, it remains to be established whether the 
accumulation of these proteins in P-bodies is the cause rather than the consequence of target 
mRNA silencing36,37. 
3. Mechanisms responsible for altered miRNA expression in gliomas 
Aberrant miRNA expression and function has been frequently observed in gliomas. A 
number of mechanisms are responsible for altered miRNA expression in cancer:  
a. Altered transcription regulation or abnormalities in miRNA processing.  
For miR-7, normal pre-miRNA levels were found to be associated with reduced mature 
miRNA levels in glioblastomas, where it was proven that the reduction in the miR-7 
processing was occurred at the pri- to pre-miRNA processing step38. Various members of 
the let-7 family are regulated post-transcriptionally during embryonic brain development, 
the neural differentiation of embryonic stem cells (SC) and in embryocarcinoma. In these 
settings, the levels of the pre-miRNAs were consistent during differentiation; however, the 
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mature forms increased 39. Few studies shed some light on this mechanism by showing that 
the let-7 targets, the RNA-binding proteins Lin28 and Lin28B, bind to the loop region of let-7 
precursors, which blocks the processing of let-7 at either the Drosha or the Dicer levels40,41. 
This Lin28-mediated degradation of let-7 likely plays a key role not only in development but 
also in tumorigenesis. 
b. Localization of miRNAs inside or close to cancer-associated genomic regions42,43.  
This mechanism was suggested also for gliomas based on an array study on human glioma 
tumors and mouse and human glioma cell lines. The study demonstrated that the majority 
of the differentially expressed miRNAs were located in regions susceptible to genetic 
alterations in cancer 20.  
c. Epigenetic regulation of miRNA expression.  
This is illustrated bychanges in chromatin structures that are induced by covalent 
modifications of histones and/or DNA methylation44. For example, the epigenetic silencing 
of the miR-124 loci has been observed in brain tumors 8 and precancerous lesions45. The 
epigenetic masking of miR-124 induces activation of the oncogene cyclin-dependent kinase 
(CDK)-6 and consequent phosphorylation of Rb, resulting in accelerated cell growth.  
It has been shown that the Let-7 family is downregulated in gliomas18. This miRNA family is 
considered to be comprised of tumor suppressor miRNAs. The let-7a-3 locus is generally 
methylated in normal tissues, but it is hypomethylated in some types of cancers. The 
methylation levels of let-7a-3 correlate inversely with let-7a-3 pri-miRNA expression levels; 
thus, Let-7a-3 hypomethylation facilitates the epigenetic reactivation of the gene resulting in 
elevated expression of let-7a-3 and enhanced tumor phenotypes and oncogenic changes39,46. 
Another example is miR-128, which is not regulated by epigenetics, but has been shown to 
play a role in the epigenesis of glioma SCs. Its downregulation in glioma tissue causes the 
elevated expression of Bmi-1, one of the polycomb group of genes that function as 
epigenetic silencers, which enhances cancer stem cell self-renewal through chromatin 
remodeling16. 
4. The involvement of miRNAs in pathways that may promote gliomagenesis 
and tumor progression 
miRNAs have been shown to act as both oncogenes or tumor suppressor genes and, thus, 
affect pathways that bestow nearly all hallmarks of cancer47,48. These miRNAs can, in turn, 
promote gliomagenesis and tumor progression. 
a. Sustaining proliferative signaling 
For a tumor to become independent from external growth factor signals, it requires the 
activation of different cell proliferation and survival pathways, such as those mediated by 
epidermal growth factor receptor (EGFR) and Akt, which play a central role in 
glioblastomas. It has been demonstrated that miR-7 directly inhibits the expression of 
EGFR38,49 and its downstream effector, Raf1, and suppresses the AKT pathway by targeting 
upstream regulators. Indeed, transfection with "mimic" miR-7 oligonucleotides decreased 
viability and invasiveness and induces cell cycle arrest and apoptosis of glioblastoma cell 
lines38,49.  
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The altered regulation/activation of RAS proteins, which process signals downstream of 
growth receptors, plays a key role in the deregulation of multiple proliferation pathways in 
most types of tumors, including gliomas. Decreased levels of let-7 in gliomas correlate 
inversely with overexpression of RAS proteins, while restoring let-7 expression reduces the 
expression of RAS in glioma cell lines resulting in tumor growth inhibition in vitro and in 
vivo18. Moreover, the activation/overexpression of RAS leads to the upregulation of miR-21 
in-vitro and in-vivo. Mir-21 exerts its oncogenic effect by downregulating the phosphatase 
and tensin homolog (PTEN) and programmed cell death 4 (PDCD4)50. In a number of 
human glioblastoma cell lines, such as T98G, A172, U87, and U251, the expression of PDCD4 
protein correlates inversely with expression of miR-21. The downregulation of miR-21 in 
those cell lines leads to decreased proliferation, increased apoptosis, and decreased colony 
formation on soft agar51.  
DNA amplification of an onco-amplicon was observed in a subset of high-grade gliomas. 
This onco-amplicon consists of miR26a-2 and the oncoproteins CDK4 and CENTG1, which 
regulate the RB1 and PI3 kinase/AKT pathways, respectively. miR-26a alone can 
functionally target PTEN, RB1, and MAP3K2/MEKK2 protein expression, thereby 
increasing AKT activation, promoting proliferation, and decreasing c-JUN N-terminal 
kinase-dependent apoptosis in vitro and in vivo. The overexpression of miR-26a in cells 
overexpressing CDK4 or CENTG1 further promotes tumor growth in vivo. Glioblastoma 
patients harboring this amplification display markedly decreased survival15,19. 
b. Evading growth suppressors  
miRNAs may also affect cell proliferation by controlling cell cycle regulators. The E2Fs 
transcription factor family plays a pivotal role in cell cycle progression. In response to 
mitogenic signaling, pRB is sequentially phosphorylated by the CDK/cyclin complexes 
leading to activation of E2F-responsive genes to promote cell cycle progression52. This 
pathway can be inhibited by several miRNAs. For example, miR-137, and miR-124a inhibit 
CDK6 expression in different cancer cell lines, including gliomas8, where the transfection of 
miR-124 or miR-137 has been shown to prevent cell cycle progression in glioblastoma cell 
lines, which is associated with the decreased expression of CDK6 and pRB proteins8. miR-
34a, which is transcriptionally activated by p53, can target both CDK6 and cyclin D1 
preventing the downstream pro-survival signaling of the cyclin/CDK pathway. Restoring 
the expression of the underexpressed miR-34a in glioma cell lines downregulates CDK6 
protein expressions and inhibits cell proliferation.12 
The negative regulators of the cyclin/CDK pathway, such as members of the Cip/Kip 
family (p21, p27 and p57) and the INK4a/ARF family (p14 and p16), are regulated by 
several miRNAs. Upregulation of these miRNAs may inhibit these negative regulators and 
result in the proliferation and survival of the cells.  
The miRNA clusters miR-106b-25 and miR-17-92 have anti-proliferative and pro-apoptotic 
activities in different tumor types through the inhibition of p21 in addition to other genes. 
Although they are also upregulated in gliomas20, their role in the inhibition of p21 or other 
negative regulators of cyclin/CDK remain to be elucidated. High levels of miR-221/222, 
which targets both p27 and p57, appear in glioblastomas. Functional studies showed that 
miR-221/222 prevents quiescence when elevated during growth factor deprivation and 
induces precocious S-phase entry, thereby triggering cell death53. In addition, the 
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overexpression of these miRNAs increases glioma cell proliferation in-vitro and induces 
glioma growth in a subcutaneous mouse model54. The inhibition of miR-10b, which is 
strongly upregulated in gliomas, reduces glioma cell growth through cell-cycle arrest and 
apoptosis. These cellular responses are mediated by augmented expression of its direct 
targets, including p21 and CDKN2A/p1655. 
c. Resisting cell death  
In addition to the role of miR-221/222 in cell growth and cell cycle progression, it has been 
demonstrated that miR-221/222 directly regulates apoptosis by targeting p53-upregulated-
modulator-of-apoptosis (PUMA) in glioblastoma. PUMA binds to Bcl-2 and Bcl-XL through 
a BH3 domain and the exogenous expression of PUMA results in an extremely rapid and 
profound apoptosis56. Thus, the forced expression of miR-221/222 downregulates PUMA 
and induces cell survival, whereas the knockdown of miR-221/222 induces PUMA 
expression and cell apoptosis as well as decreases tumor growth in a xenograft model57.  
d. Inducing angiogenesis 
Recent studies have revealed important roles for miRNAs such as the endothelial cell (EC)-
restricted miRNA miR-126 as well as miR-378, miR-296, miR-92a and the miR-17-92 cluster 
in regulating angiogenesis. Thus, these have been termed angiomirs58.  
The level of the angiomir miR-296, which inhibits the degradation of the VEGF receptor, is 
increased in EC cells co-cultured with glioma cells or in response to angiogenic growth 
factors (including VEGF). When miR-296 is inhibited in vivo, the vascularization of tumor 
xenografts decreases59. miR-93, one of the miRNAs within the miR-106b-25 cluster, a 
member of the miR-17 family, enhances cell survival, promotes sphere formation and 
augments tumor growth. In vivo studies revealed that miR-93-expressing cells induced 
blood vessel formation, likely through targeting integrin-β8, allowing blood vessels to 
extend to tumor tissues in high densities. These findings show that miR-93 promotes tumor 
growth and angiogenesis through the suppression of integrin-β8 expression.  
e. Activating invasion and metastasis 
As mentioned above, miR-21 is overexpressed in gliomas. The metalloproteinase (MMPS) 
inhibitors RECK and TIMP3 are two targets of miR-21. RECK is a membrane-anchorage 
regulator, while TIMP3 is an extracellular matrix (ECM)-bound protease inhibitor. 
Treatment with antisense oligonucleotides to miR-21 in glioma cell lines and in a nude 
mouse model of human glioma resulted in elevated levels of RECK and TIMP3 and, 
therefore, reduced MMP activities. Thus, downregulation of miR-21 in glioma cells leads to 
a decrease in their migratory and invasion abilities11.  
miR-10b is highly expressed in many tumors, including glioblastomas. It was found that 
miR-10b induces glioma cell invasion by modulating the expression of the tumor invasion 
factors MMP-14 and uPAR through directly targeting HOXD10. Accordingly, glioma cells 
lost their invasive ability when they were treated with specific antisense oligonucleotides to 
miR-10b.  
Not surprisingly, additional miRNAs are currently being identified and associated with 
ECM reorganization in relationship to cancer. Like miR-21 and 10b, miR-146b has also been 
demonstrated to play a role in glioma cell invasion60. However, miR-146b does not function 
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through the suppression of ECM inhibitors; rather, its loss in gliomas allows the 
upregulation of MMP16, which might cause proteolysis of ECM components, such as type 
III collagen. Thus, low levels of miR-146b contribute to the migration and invasion of 
glioma60. 
f. Reprogramming energy metabolism 
Pyruvate kinase type M2 (PKM2) is one of four isoenzymes of pyruvate kinase, which 
catalyzes the last step within glycolysis. This enzyme is normally thought to be 
embryonically restricted; however, it has been shown to be expressed in cancerous cells61. 
Recently, it was shown that the levels of PKM2 negatively correlate with the levels of miR-
326, suggesting a regulatory relationship between PKM2 and miR-326. Furthermore, miR-
326 decreased the glioma metabolic activity by decreasing ATP levels, suggesting that miR-
326 could regulate glioma metabolism through the downregulation of PKM262. 
5. The glioma microRNA expression signature  
Differential miRNA expression in gliomas was first reported by Ciafre`63 and Chan64. Their 
study revealed that miR-2164 and miR-221 are upregulated, whereas miR-128, miR-181a, 
miR-181b and miR-181c are downregulated, in glioblastoma63. Other array-based 
approaches identified that the expression of miR-124, miR-128a, and miR-137 are decreased 
in anaplastic astrocytomas and glioblastomas8. In addition, miR-124 is decreased in 
oligodendroglial tumors65 relative to non-neoplastic control brain tissues.  
The expression levels of miR-124 and miR-137 were increased during the differentiation of 
mouse neural progenitor cells (NPCs) following growth factor withdrawal. Thus, the 
authors have suggested that these specific miRNAs display “stemness” of glioma cells and 
that alteration of the levels of these miRNAs may induce differentiation8.  
While these studies compared microRNA expression in gliomas relative to control tissues, 
other studies explored the role of miRNAs in glioma progression. One study investigated 
miRNA expression profiles in primary WHO grade II gliomas that spontaneously 
progressed to WHO grade IV secondary glioblastomas. They identified 12 miRNAs (miR-9, 
miR-15a, miR-16, miR-17, miR-19a, miR-20a, miR-21, miR-25, miR-28, miR-130b, miR-140 
and miR-210) that were upregulated and two miRNAs (miR-184 and miR-328) that were 
downregulated upon glioma progression66. Other studies have compared the differential 
miRNA expression between astrocytomas and glioblastomas and revealed a 23-miRNA 
expression signature that can discriminate glioblastomas from anaplastic astrocytomas with 
an overall diagnostic accuracy of 89.7%67. 
Our study compared the miRNA expression signatures of glial tumors, embryonic SCs, 
NPCs and normal adult brains from both human and mouse tissues. We demonstrated that 
all gliomas displayed NPC-like miRNA signatures. About half of the miRNAs expressed in 
the NPCs-glioma shared profile were clustered in seven genomic regions. These clusters 
comprised the miR17 family (3 clusters), miR183-182, and the SC-specific clusters miR367-
302 and miR371-373, which are upregulate. They also contained the bipartite cluster of 7+46 
miRNAs on chromosome 14q32.31, which is downregulated in the shared expression 
profile. These seven regions are particularly prone to genetic and/or epigenetic aberrations 
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in different types of cancers (e.g., LOH on chromosome 14q32.31, or the amplification of 
chromosome 13q31.3). Together, these findings suggest that NPCs may be the originating 
cells in gliomas and that aberrations in critical regions might be necessary to maintain the 
stem cell nature of gliomas20.  
A recent paper analyzed microRNA expression data from The Cancer Genome Atlas 
(TCGA) and identified five clinically and genetically distinct glioblastoma subclasses related 
to a different neural precursor cell types. Thus, like us they also suggested that 
glioblastomas can arise from neural precursor cells but emphasized that the cell of origin 
could arise from multiple stages of differentiation68. 
6. microRNAs as biomarkers for the diagnosis and prognosis of gliomas 
As reviewed above, a large number of recent studies have discovered that miRNAs play 
important regulatory roles in a variety of cellular functions in gliomas. Other papers have 
demonstrated that miRNAs can be used for tumor classification and grading66,67 in 
addition to the diagnosis23, prognosis22,23 and prediction of therapeutic efficacy69, 69 of 
tumors. The discovery of miRNAs in the serum of cancer patients70 opened up the 
exciting possibility of using miRNAs as non-invasive biomarkers. Thus, detecting and 
quantifying microRNAs may soon be used in routine clinical practice for diagnostic and 
prognostic glioma testing. 
The expression levels of miR-18222 and miR-19623 are significant in correlation with World 
Health Organization glioma grading (P < 0.001). Multivariate analysis showed that the 
expression of both these miRNAs is a predictor of overall survival in glioblastoma patients 
22,23. Analysis of miRNA expression data in glioblastoma patients (n = 222) derived from the 
TCGA dataset identified an expression signature of ten miRNAs that can predict 
glioblastoma (GBM) patient survival71. In astrocytomas, the downregulation of miR-137 has 
been shown to be associated with advanced clinical stages of the disease; and the low 
expression levels of miR-181b and miR-106a, or high expression of miR-21, are significantly 
associated with poor patient survival24. Several papers aimed to identify the miRNAs 
specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma. 
In one article, the authors established resistant variant U251R cells from a TMZ-sensitive 
glioblastoma cell line (U251MG) and performed miRNA microarray on both the resistant 
and sensitive cell lines. The results showed that miR-195, miR-455-3p and miR-10a* were the 
three most upregulated miRNAs in the resistant cells. When miR-195 was reduced, the 
resistant cells displayed a moderate cell killing effect, and the combination with TMZ 
strongly enhanced this effect25. Another article examined the correlation between the 
expression levels of selected microRNAs in 22 primary glioblastomas with response to 
concomitant therapy (e.g., chemoradiotherapy with TMZ). They found that miR-181b and 
miR-181c were significantly downregulated in patients who responded to concomitant 
therapy compared to patients with progredient disease26.  
Over many decades, it has been shown that cell-free DNA and RNA is present in the 
circulation and may represent potential biomarkers. We have demonstrated that tumor-
specific DNA can be detected in the serum of glioma patients and is a potentially 
promising tool for brain tumor diagnosis72. Skog et al. was the first to demonstrate that 
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brain microvascular endothelial cells take up exosomes, which contain mRNA, miRNA, 
and angiogenic proteins released by glioblastoma cells. Moreover, they showed that miR-
21 is more elevated in serum microvesicles from glioblastoma patients than in healthy 
controls73.  
Based on their potential as prognostic and diagnostic biomarkers, circulating miRNAs are 
promising non-invasive tumor markers. Tumor-specific circulating miRNAs may improve 
cancer diagnosis and prognosis because, as described above, several promising miRNAs 
have already been recognized as potential biomarkers for gliomas. 
7. The therapeutic potential of microRNAs in gliomas 
With the increased understanding of the miRNA target genes, the cellular behaviors 
influenced by them and the ability of one microRNA, such as let-7 or miR-21, to target more 
than one gene or pathway provide exciting opportunities to use miRNAs or their inhibitors 
as potential candidates for the treatment of brain tumors.  
There have been few pre-clinical and phase I/II studies that showed some success in using 
synthetic miRNA mimics or anti-miRNA oligonucleotides as therapeutic agents. Two of 
these studies demonstrated that delivery of the locked-nucleic-acid (LNA)-anti-miR in 
African green monkeys silences miR-122, decreases the total plasma cholesterol74 and 
suppresses HCV viremia75 with no evidence of hepatotoxicity. Another study showed that 
the silencing of miR-155 in a mouse inflammation model by LNA-anti-miR administration 
results in derepression of the C/EBP Beta isoforms and downregulation of granulocyte-
colony stimulating factor expression in mouse splenocytes76. In gliomas, the silencing of 
miR-21 by LNA-anti-miR followed by TRAIL treatment increased caspase activity in vitro 
and reduced tumor growth in vivo10. These results support the potential of LNA-anti-miR as 
therapeutics for inhibition of disease-associated miRNAs.  
An alternative to chemically modified antisense oligonucleotides is the "miR sponge". These 
competitive miR inhibitors contain multiple binding sites to an miR of interest, preventing it 
from binding to its natural target. In this way, a single sponge can block all miR family 
members containing the same seed sequences. The sponge strategy has been used to inhibit 
miR-31 in vivo in a noninvasive breast cancer cell line. miR sponges that carried miR-31 
recognition motifs were introduced into a retroviral vector and reduced miR-31 function 
significantly77.  
Some preclinical studies have shown promising results using self-complementary adeno-
associated viral (scAAV) vectors. For example, a scAAV vector containing miR-26a was 
administered with a single tail-vein injection into mice with established liver tumors. High 
miR-26a levels were found in their livers and no toxic effects were observed. While six out of 
eight mice treated with the control virus developed tumors, eight out of ten miR-26a-treated 
mice developed only small tumors or had a complete absence of tumors78.  
Although most of these therapeutic approaches appear promising for systemic tumors, they 
would be considerably challenging in brain tumors due to several obstacles and barriers in 
vivo, such as the blood–brain barrier27, which might prevent the miRNAs or their 
antagonists from entering the brain. Thus, the development of more efficient and specific 
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delivery systems is necessary before miRNAs can be used as therapeutic agents for the 
treatment of malignant gliomas.  
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